Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

2.

Association between inflammatory back pain features, acute and structural sacroiliitis on MRI, and the diagnosis of spondyloarthritis.

Kivity S, Gofrit SG, Baker FA, Leibushor N, Tavor S, Lidar M, Eshed I.

Clin Rheumatol. 2019 Jun;38(6):1579-1585. doi: 10.1007/s10067-019-04432-5. Epub 2019 Jan 10.

PMID:
30628016
3.

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A.

Leukemia. 2017 Nov;31(11):2336-2346. doi: 10.1038/leu.2017.82. Epub 2017 Mar 10.

PMID:
28280274
4.

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C.

Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.

5.

The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.

Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C.

Blood. 2016 Apr 21;127(16):1998-2006. doi: 10.1182/blood-2015-08-665034. Epub 2016 Feb 11.

PMID:
26869395
6.

Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.

Ellis MH, Lavi N, Mishchenko E, Dally N, Lavie D, Courevitch A, Gutwein O, Bulvik S, Braester A, Chubar E, Tavor S, Duek A, Kirgner I, Koren-Michowitz M.

Leuk Res. 2015 Aug 12. pii: S0145-2126(15)30356-8. doi: 10.1016/j.leukres.2015.08.003. [Epub ahead of print]

PMID:
26364797
7.

Role of CXCR4 in the pathogenesis of acute myeloid leukemia.

Peled A, Tavor S.

Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.

8.

High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.

Tavor S, Rahamim E, Sarid N, Rozovski U, Gibstein L, Aviv F, Kirsner I, Naparstek E.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):438-43. doi: 10.1016/j.clml.2012.05.007. Epub 2012 Sep 25.

PMID:
23017331
9.

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?

Barak AF, Bonstein L, Lauterbach R, Naparstek E, Tavor S.

Hematol Rep. 2011 Oct 19;3(3):e29. doi: 10.4081/hr.2011.e29. Epub 2011 Dec 6.

10.

Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.

Tavor S, Rothman R, Golan T, Voskoboinik N, Katz BZ, Sarid N, Shomrat R, Orr-Urtreger A, Naparstek E.

Leuk Lymphoma. 2011 Apr;52(4):642-7. doi: 10.3109/10428194.2010.551571. Epub 2011 Feb 16.

PMID:
21323513
11.

Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?

Tavor S, Petit I.

Semin Cancer Biol. 2010 Jun;20(3):178-85. doi: 10.1016/j.semcancer.2010.07.001. Epub 2010 Jul 15. Review.

PMID:
20637871
12.

The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?

Katz BZ, Tavor S.

Leuk Lymphoma. 2009 Jul;50(7):1067-8. doi: 10.1080/10428190902991837. No abstract available.

PMID:
19557626
13.

Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.

Dezorella N, Pevsner-Fischer M, Deutsch V, Kay S, Baron S, Stern R, Tavor S, Nagler A, Naparstek E, Zipori D, Katz BZ.

Exp Cell Res. 2009 Jul 1;315(11):1904-13. doi: 10.1016/j.yexcr.2009.03.016. Epub 2009 Mar 27.

PMID:
19328780
14.

Engraftment of human blood malignancies to the turkey embryo: a robust new in vivo model.

Grinberg I, Reis A, Ohana A, Taizi M, Cipok M, Tavor S, Rund D, Deutsch VR, Goldstein RS.

Leuk Res. 2009 Oct;33(10):1417-26. doi: 10.1016/j.leukres.2009.02.009. Epub 2009 Mar 17.

PMID:
19297019
15.

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.

Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K, Kay S, Baron S, Amariglio N, Deutsch V, Naparstek E, Rechavi G.

Leukemia. 2008 Dec;22(12):2151-5158. doi: 10.1038/leu.2008.238. Epub 2008 Sep 4.

PMID:
18769446
16.

Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.

Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, Goichberg P, Tesio M, Netzer N, Naparstek E, Hardan I, Nagler A, Resnick I, Tsimanis A, Lapidot T.

Cancer Res. 2006 Nov 15;66(22):11013-20.

17.

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.

Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D.

Leukemia. 2006 Dec;20(12):2147-54. Epub 2006 Oct 12.

PMID:
17039238
18.

Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice.

Tavor S, Petit I, Porozov S, Goichberg P, Avigdor A, Sagiv S, Nagler A, Naparstek E, Lapidot T.

Blood. 2005 Sep 15;106(6):2120-7. Epub 2005 Jun 7.

PMID:
15941909
19.

Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia.

Monaco G, Belmont JW, Konopleva M, Andreeff M, Tavor S, Petit I, Kollet O, Lapidot T.

Cancer Res. 2004 Sep 15;64(18):6832 author reply 6832-3. No abstract available.

20.

CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T.

Cancer Res. 2004 Apr 15;64(8):2817-24.

21.

Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation.

Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP.

J Biol Chem. 2003 Dec 26;278(52):52651-9. Epub 2003 Sep 29.

22.

C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.

Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U, Fermin AC, Heaney A, Miller CW, Koeffler HP.

Leuk Res. 2002 May;26(5):451-7.

PMID:
11916518
23.

Macrophage functional maturation and cytokine production are impaired in C/EBP epsilon-deficient mice.

Tavor S, Vuong PT, Park DJ, Gombart AF, Cohen AH, Koeffler HP.

Blood. 2002 Mar 1;99(5):1794-801.

PMID:
11861297
24.

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.

Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A.

Int Immunol. 2002 Feb;14(2):121-9.

PMID:
11809731
25.

Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.

Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S, Koeffler HP.

Genes Chromosomes Cancer. 2002 Jan;33(1):17-21.

PMID:
11746983
26.

Analysis of the CHK2 gene in lymphoid malignancies.

Tavor S, Takeuchi S, Tsukasaki K, Miller CW, Hofmann WK, Ikezoe T, Said JW, Koeffler HP.

Leuk Lymphoma. 2001 Jul;42(3):517-20.

PMID:
11699418
27.

Pathogenic anti-endothelial cell antibodies: classification to anti-microvascular EC and anti-macrovascular EC antibodies.

Shoenfeld Y, Praprotnik S, Levy Y, Tavor S, Boffa MC, Barkai G, Eldor A, Blank M.

Isr Med Assoc J. 2000 Dec;2 Suppl:24-5. No abstract available.

28.

Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias.

Hofmann WK, Miller CW, Tsukasaki K, Tavor S, Ikezoe T, Hoelzer D, Takeuchi S, Koeffler HP.

Leuk Res. 2001 Apr;25(4):333-8.

PMID:
11248330
29.

Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells.

Praprotnik S, Blank M, Levy Y, Tavor S, Boffa MC, Weksler B, Eldor A, Shoenfeld Y.

Int Immunol. 2001 Feb;13(2):203-10.

PMID:
11157853
30.

A mouse model for heparin-induced thrombocytopenia.

Blank M, Eldor A, Tavor S, Ziporen L, Cines DB, Arepally G, Afek A, Shoenfeld Y.

Semin Hematol. 1999 Jan;36(1 Suppl 1):12-6.

PMID:
9930558

Supplemental Content

Support Center